Hypoalbuminemia

Transcenta Presented Safety / Tolerability and Preliminary Anti-tumor Activity Data in Gastric and Pancreatic Cancers of TST001 Monotherapy from China Phase I Clinical Trial at the 2022 International Gastric Cancer Congress

Retrieved on: 
Thursday, March 10, 2022
Safety, Trial of the century, Social conditioning, Orphan, ADCC, Research, Therapy, DLT, FDA, EVP, III, Suzhou Industrial Park, Cancer, Vomiting, PRS, Nature, China Media Group Headquarters, News, Anemia, AUC, Cmax, Headquarters, Stomach, CDC, Nausea, Discovery, Patient, Stomach cancer, MTD, HKEX, Pancreatic cancer, Process, CMO, Standard of care, Constipation, Environment, PK, NK, HER2, Fucose, PD-L1, ICB, IGCC, Abdominal distension, AES, Pharmaceutical industry, Medical imaging, Hypoalbuminemia

TST001 demonstrated a roughly linear PK profile as both Cmax and AUC increased proportionally across the dose range following the first dose.

Key Points: 
  • TST001 demonstrated a roughly linear PK profile as both Cmax and AUC increased proportionally across the dose range following the first dose.
  • Post the data cut-off date, additional confirmed PRs were observed at recommended phase 2 dose in the newly enrolled monotherapy expansion cohorts including gastric cancer and pancreatic cancer patients with Claudin18.2 expression.
  • TST001, a high affinity Claudin18.2 humanized antibody, is safe and displayed promising anti-tumor activity in Claudin18.2 over-expressing gastric and pancreatic cancer patients."
  • In recent years, Claudin18.2 has emerged as a promising cancer treatment target for gastric cancer beyond HER2 and PD-L1.

European Commission Approves TEPMETKO® (tepotinib) for Patients with Advanced NSCLC with METex14 Skipping Alterations

Retrieved on: 
Friday, February 18, 2022
Research, Radiology, Pharmaceutical, Oncology, Technology, Genetics, Clinical Trials, Science, Biotechnology, Nursing, Other Technology, Health, Other Science, Pneumonitis, Medicine, Lung cancer, Electronics, Death, Adult, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, European Commission, DDR, Entrepreneurship, Royal commission, The New England Journal of Medicine, AST, European, ALT, Edema, Merck Serono, Phase, Diarrhea, Cerebral edema, Health care, Neoplasm, Creatinine, Diagnosis, Merck Millipore, Netherlands Cancer Institute, Government, ILD, Health, Review, Large-cell lung carcinoma, Gene editing, Hypoalbuminemia, Interstitial lung disease, EU, Cancer, Policy, NSCLC, EGFR, EC, Patient, Food, Science, Immunotherapy, MET, QT interval, Phase II, Nausea, Intelligence, Toxicity, Pharmaceutical industry, Medical imaging, Merck, the VISION Study, TEPMETKO® (tepotinib), Merck, THE VISION STUDY, TEPMETKO® (TEPOTINIB), MERCK

The approval of TEPMETKO provides a much-needed targeted treatment option for patients with advanced non-small cell lung cancer with METex14 skipping alterations, said Professor Egbert Smit, a VISION study investigator at the Netherlands Cancer Institute.

Key Points: 
  • The approval of TEPMETKO provides a much-needed targeted treatment option for patients with advanced non-small cell lung cancer with METex14 skipping alterations, said Professor Egbert Smit, a VISION study investigator at the Netherlands Cancer Institute.
  • TEPMETKO has demonstrated durable and consistent response rates and has the potential to significantly help patients with this challenging cancer.
  • The approval is based on results from the pivotal Phase II VISION study evaluating TEPMETKO as monotherapy in patients with advanced NSCLC with METex14 skipping alterations.
  • Based on the 01 February 2021 data cut, 275 patients with a median age of 72.6 years with advanced or metastatic NSCLC with METex14 skipping alterations have been analyzed.

New Studies Demonstrate Role of High-Flux Dialyzers in Managing Albumin

Retrieved on: 
Thursday, July 29, 2021
Blood proteins, Branches of biology, Medicine, Hypoalbuminemia, Anatomy, Serum albumin, Serum, Albumin, Hemodialysis

This real-world analysis evaluated the performance of four high-flux dialyzers with varying surface areas in 271 patients with baseline hypoalbuminemia.

Key Points: 
  • This real-world analysis evaluated the performance of four high-flux dialyzers with varying surface areas in 271 patients with baseline hypoalbuminemia.
  • "This study further demonstrates that high-flux dialyzers can play a role in increasing albumin levels, and especially for those patients with higher body mass index and inflammation."
  • "These results further reinforce the important role that high-flux dialyzers like Optiflux can play in helping address the potential dangers of low serum albumin levels."
  • The authors note that "excessive" loss of albumin is a theoretical concern with the chronic use of increasingly permeable dialyzers.